Cationic Progesterone Lipid Derivatives Targeting PI3K/AKT Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current progesterone-based therapeutics face challenges in effectively targeting both progesterone receptor-positive and negative cancer cells while minimizing toxicity to healthy cells, and they often fail to exert anticancer activity due to persistent activation of the PI3K/AKT pathway.
Innovation Solution
Development of cationic lipid modified progesterone derivatives with specific structural modifications, such as varying alkyl chain lengths and functional groups, which are synthesized through a process involving reduction, oxidation, and quaternization, to confer cytotoxicity specifically on cancer cells and inhibit the PI3K/AKT pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If progesterone-based therapeutics are used to target cancer cells, then anticancer activity is achieved, but toxicity to healthy cells increases
Solution Approach 1:
The patent applies local quality by modifying the progesterone molecule with specific cationic lipid groups at particular positions (C17 hydroxyl group) to create compounds with enhanced anticancer activity against both PgR-positive and PgR-negative cells while reducing general toxicity. The cationic lipid modification at specific locations on the progesterone backbone creates localized functional changes that selectively affect cancer cells
Solution Approach 2:
The patent employs parameter changes by systematically varying the alkyl chain length (C6, C8, C10, C12, C14, C16) and structure of the cationic lipid groups attached to progesterone. This structural parameter modification allows optimization of the balance between anticancer efficacy and selectivity, with different chain lengths providing different degrees of membrane interaction and cellular uptake characteristics
2Adaptability or versatility
If progesterone derivatives are designed to target both PgR-positive and PgR-negative cancer cells, then versatility is improved, but selectivity and reduced toxicity to healthy cells becomes more difficult
Solution Approach 1:
The patent achieves universality by designing cationic lipid-modified progesterone derivatives that can function against both PgR-positive and PgR-negative cancer cells through multiple mechanisms. The compounds exhibit dual functionality: they can bind to progesterone receptors in PgR-positive cells while also inducing apoptosis in PgR-negative cells through PI3K/AKT pathway inhibition, making them universally effective across different cancer subtypes
Solution Approach 2:
The patent creates composite molecular structures by combining progesterone (a natural hormone with receptor binding capability) with cationic lipid groups (which provide membrane interaction and apoptotic induction properties). This composite structure integrates the benefits of both components: the progesterone portion provides specificity for PgR-positive cells while the cationic lipid portion adds activity against PgR-negative cells and enhances overall anticancer efficacy
3Ease of operation
If conventional progesterone therapeutics are used, then treatment is simple, but the PI3K/AKT pathway remains activated reducing anticancer efficacy
Solution Approach 1:
The patent applies the taking out principle by removing the limitation of conventional progesterone therapy that relies solely on PgR-mediated pathways. By extracting and adding the cationic lipid component, the invention creates a new compound class that operates through additional mechanisms (direct membrane interaction, apoptotic pathway activation) independent of PI3K/AKT pathway status, thereby overcoming the resistance caused by persistent pathway activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cationic lipid modified progesterone derivatives exhibit potent anticancer activity by arresting cancer cells in the G2/M phase, inducing apoptosis, and inhibiting tumor growth, with minimal toxicity to non-cancerous cells and significant anti-angiogenic effects.
Implementation Method 1
reducing progesterone with lithium aluminium hydride
Implementation Method 2
regioselective oxidation by Manganese dioxide
Implementation Method 3
reacting tertiary amine compound obtained in step (b) using alkyl halide
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A
AI summary
The present invention relates to the development of the cationic progesterone compounds of formula 6 as a novel anti-tumor agent. The present invention provides a method for the preparation of novel series of progesterone derivatives of formula 6. The invention also provides information related to highly selective anti-cancer activities of these compounds in wide range of cancer cell irrespective of their progesterone receptor status. Thus, the presently disclosed cationic progesterone compounds offer a viable option as anti-cancer therapeutics.